Corvus Pharmaceuticals, Inc. (CRVS) Stock Price
CRVSStock
$14.56+153.87%52W
Market Cap$1.22B
P/E—
PEG Ratio—
Div yield—
Beta1.49
CRVS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-33.36%
Price vs S&P 500 (4W)2.81%
VGM Score57.88
CRVS Earnings Surprise History
Q2 25-0.13est. -0.12
Q3 25-0.12est. -0.14
Q4 25-0.15est. -0.13
Q1 26-0.15est. -0.15
Q2 26-0.19est. -0.17
CRVS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.23
4.23
4.23
4.29
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CRVSCorvus Pharmaceuticals, Inc. | — | — | C | $14.56 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing immunotherapies that target proteins critical to T cell function and activation. Its lead candidate, soquelitinib, is designed to inhibit ITK to modulate T cell responses in immune-mediated disorders. The company also develops Ciforadenant and Mupadolimab, addressing complementary immune-regulation pathways.